JLJennifer L. Larsen

Jennifer L. Larsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jennifer L. Larsen has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • James Lane

    Departments of Internal Medicine

    3 shared publications
  • Judi Erickson

    Department of Internal Medicine, University of 983020 Nebraska Medical Center, Omaha, USA

    3 shared publications
  • Vijay Shivaswamy

    UNMC and VA Nebraska-Western Iowa Health Care System

    3 shared publications
  • Christopher Colling

    Department of Internal Medicine, University of Nebraska Medical Center and Nebraska Health System, Omaha, NE, USA

    2 shared publications
  • Elizabeth Lyden

    Preventive and Societal Medicine, University of Nebraska Medical Center and Nebraska Health System, Omaha, NE, USA

    2 shared publications
  • Elizabeth R. Lyden

    Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE

    2 shared publications

Latest Publications

  • Open Access

    Management of the Hospitalized Transplant Patient

    by Brian Boerner, Vijay Shivaswamy, Whitney Goldner, Jennifer Larsen

    Significant hyperglycemia is commonly observed immediately after solid organ and bone marrow transplant as well as with subsequent hospitalizations. Surgery and procedures are well known to cause pain and stress leading to secretion of cytokines and other hormones known to aggravate insulin action. Immunosuppression required for transplant and preexisting risk are also major factors. Glucose control improves outcomes for all hospitalized patients, including transplant patients, but is often more challenging to achieve because of frequent and sometimes unpredictable changes in immunosuppression doses, renal function, and nutrition. As a result, risk of hypoglycemia can be greater in this patient group when trying to achieve glucose control goals for hospitalized patients. Key to successful management of hyperglycemia is regular communication between the members of the care team as well as anticipating and rapidly implementing a new treatment paradigm in response to changes in immunosuppression, nutrition, renal function, or evidence of changing insulin resistance.


  • Approach to the Hospitalized Patient with Severe Insulin Resistance

    by Jennifer Larsen, Whitney Goldner

    Glucose control improves outcomes in the hospitalized patient, particularly patients on prolonged ventilator support, after acute myocardial infarction or after coronary artery bypass surgery. An iv insulin algorithm is the standard of care for initial treatment of significant hyperglycemia in the hospitalized patient, and it can be transitioned to periodic sc insulin once the patient is more stable. However, illness, medications, the endocrine and inflammatory response to stress, and pain can all contribute to insulin resistance and further aggravate preexisting insulin resistance caused by obesity. Glucose treatment goals have been established to guide the rapy, but achieving those goals can be more challenging in the presence of severe insulin resistance. When target glucose values are not achieved with established insulin algorithms, the practitioner should evaluate for potential causes of insulin resistance from technical factors that cause "pseudo-insulin resistance" as well as other modifiable factors, such as electrolyte disorders, parenteral and enteral nutrition, or other medications. Published glucose guidelines provide glucose "goals" to guide changes in the insulin algorithm, but these goals may be difficult to achieve in all individuals. We propose a stepwise approach to evaluate and treat severe insulin resistance in the hospitalized patient in order to achieve glucose goals in a timely fashion.


  • Association of Vascular Risk Factors With Carotid Intima Media Thickness After Kidney Transplant

    by Jennifer L. Larsen, Gerald C. Groggel, Jillian M. Witte, Terica L. Hudson, Elizabeth R. Lyden, Fang Yu, Urmila Mukherjee, Brian R. Stevens

    Background. Vascular risk remains the greatest cause of mortality after kidney transplant (KTX). Carotid intima media thickness (CIMT) has not been studied after KTX. We have analyzed a cross section of KTX recipients to determine which risk factors best correlate with CIMT, representing vascular risk. Methods. All recipients 6 or more months after KTX with estimated glomerular filtration rate (GFR) ≥30 mL/min were invited to participate. Biomarkers of vascular risk were compared with CIMT. Results. A total of 342 recipients (192 men/150 women) with mean age of 52.3±0.6 years (±standard error of the mean) were studied 5.9±0.3 years since KTX (range: 0.5–33.7 years). Diabetes (PP=0.01), and donor status (deceased vs. living) (P=0.04) were associated with CIMT. Age (PP=0.0026), systolic blood pressure (P=0.0013), and pulse pressure (PP=0.0002) and pulse pressure (P=0.007). In multivariate analysis, race/ethnicity, GFR, as well as age, BMI, diabetes status, systolic and diastolic blood pressures, and pulse pressure were all independently associated with CIMT (P<0.05). There was no correlation between CIMT and lipids, homocysteine, high-sensitive C-reactive protein, 25-hydroxyvitamin D, or parathyroid hormone (PTH). Conclusions. In the largest study of CIMT after KTX, diastolic blood pressure was negatively correlated with vascular risk, whereas age, diabetes, BMI, systolic blood pressure, race/ethnicity, and GFR independently correlated with CIMT after KTX confirming the value of CIMT as a noninvasive means to assess vascular risk and factors unique to this patient population.

  • Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal sprague–dawley rats

    by Vijay Shivaswamy, Marissa McClure, Joel Passer, Christin Frahm, LuAnn Ochsner, Judi Erickson, Robert G. Bennett, Frederick G. Hamel, Jennifer L. Larsen

    Post-transplant diabetes mellitus (PTDM) worsens outcomes after kidney transplantation, and immunosuppression agents contribute to PTDM. We have previously shown that tacrolimus (TAC) and sirolimus (SIR) cause hyperglycemia in normal rats. While there is little data on the mechanism for immunosuppressant-induced hyperglycemia, we hypothesized that the TAC and SIR-induced changes are reversible. To study this possibility, we compared normal rats treated for 2 weeks with either TAC, SIR, or a combination of TAC and SIR prior to evaluating their response to glucose challenge, with parallel groups also treated for 2 weeks after which treatment was stopped for 4 weeks, prior to studying their response to glucose challenge. Mean daily glucose and growth velocity was decreased in SIR, and TAC+SIR-treated animals compared to controls (P < 0.05). TAC, SIR, and TAC+SIR treatment also resulted in increased glucose response to glucose challenge, compared to controls (P < 0.05). SIR-treated animals also had elevated insulin concentrations in response to glucose challenge, compared to controls (P < 0.05). Insulin content was decreased in TAC and TAC+SIR, and islet apoptosis was also increased after TAC+SIR treatment (P < 0.05). Four weeks after treatments were stopped, all differences resolved between groups. In conclusion, TAC, SIR, and the combination of TAC+SIR-induced changes in glucose and insulin responses to glucose challenge that were accompanied by changes in islet apoptosis and insulin content. These changes were no longer present 4 weeks after cessation of therapy suggesting immunosuppressant-induced changes in glucose metabolism are likely reversible.


  • Dyslipidemia Can Be Controlled in Diabetic as Well as Nondiabetic Recipients After Kidney Transplant

    by Vijay Shivaswamy, R Brian Stevens, Ramona Zephier, Myhra Zephier, Junfeng Sun, Gerald Groggel, Judi Erickson, Jennifer Larsen

    Background. Patients with diabetes have been reported to have greater dyslipidemia after kidney transplant (KTX). Because postKTX management of diabetes has changed markedly since those reports, we hypothesized that lipids can be controlled as well in diabetic as in nondiabetic recipients. Methods. We compared lipid levels up to 2 years after KTX (n=192) between diabetic and nondiabetic recipients. The cohort was subdivided into nondiabetic (nonDM-K; n=123), type 2 (DM2-K; n=33), or type 1 diabetes after KTX (DM1-K; n=14), or type 1 after kidney-pancreas transplant (DM1-KP; n=22). Results. Mean age and body mass index of DM2-K were greater than the others (PPPP=0.02), and triglyceride levels were unchanged after KTX for all groups. A1C improved in DM1-K and DM1-KP (PP<0.05). Conclusions. Multiple mechanisms may contribute to better lipid levels in both groups as well as the lack of difference between diabetic and nondiabetic recipients compared with what has been reported previously: greater use of and more effective lipid-lowering agents, no significant weight gain, no difference in renal function between groups, and better control of glucose in the diabetic group. Thus, overall, lipids can be controlled as well in diabetic as in nondiabetic KTX recipients.


  • Tacrolimus and Sirolimus Cause Insulin Resistance in Normal Sprague Dawley Rats

    by Jennifer L. Larsen, Robert G. Bennett, Tab Burkman, Ana Lisa Ramirez, Sakura Yamamoto, James Gulizia, Stanley Radio, Frederick G. Hamel

    Tacrolimus-sirolimus immunosuppression has improved islet graft survival but may affect islet function. We studied the effects of tacrolimus, sirolimus, or both in normal adult male Sprague Dawley rats. Glucose and insulin response to oral glucose load and pancreas pathology were evaluated after two weeks of daily tacrolimus (1–8 mg/kg/day), sirolimus (0.08–8 mg/kg/day), or low-dose sirolimus (0.08 mg/kg/day) plus tacrolimus (1 mg/kg/day) treatment compared to controls. Tacrolimus and sirolimus each caused dose-dependent hyperglycemia with hyperinsulinemia in response to oral glucose compared to controls, suggesting insulin resistance. At the highest doses of sirolimus, fasting insulin concentrations were high and did not increase with oral glucose suggesting loss of first phase insulin release. The combination of low doses of tacrolimus and sirolimus, at concentrations used in clinical transplantation, resulted in hyperglycemia without hyperinsulinemia after oral glucose administration. The combination of tacrolimus and sirolimus decreased islet size, and increased islet apoptosis more than either medication alone, or controls. In summary, short-term therapy with either tacrolimus or sirolimus causes insulin resistance in normal rats. Combination tacrolimus-sirolimus causes greater islet changes suggesting early islet failure.


  • Greater early pancreas graft loss in women compared with men after simultaneous pancreas–kidney transplantation

    by Christopher Colling, R Brian Stevens, Elizabeth Lyden, James Lane, Lynn Mack‐Shipman, Lucile Wrenshall, Jennifer Larsen

    Abstract: Background:  Gender differences in graft survival has been reported after some types of organ transplantation, but not after pancreas transplantation. This study compares graft survival between women and men after simultaneous pancreas–kidney transplantation (SPK).Methods:  All first time SPK (n = 163) transplants (109 M/54 F) performed between 1989 and 2000 at University of Nebraska Medical Center, where data was available, were analyzed for overall graft and patient survival. Graft failure was then subdivided into early (6 months), and compared between women and men.Results:  The 5‐yr pancreas and kidney graft survival rates for all SPK recipients was 86% [95% confidence interval (CI) = 81–92%] and 87% (95% CI = 82–93%), respectively. While overall pancreas graft survival in women was similar to men (p = 0.16), early pancreas graft failure was greater in women than men (p = 0.010) with no one cause for failure predominant. There was no gender difference in late pancreas graft failure or in early, or late kidney graft failure in the same recipients. The gender difference was unexplained by differences in age, immunosuppression, body mass index (BMI), or diabetes duration between women and men.Conclusions:  This is the first report of a gender difference in pancreas graft survival after SPK with greater early (<6 months) pancreas graft failure in women than men. With no gender difference in kidney graft failure in the same individuals, gender differences in immune responses are unlikely to be the cause. Multiple variables likely contribute.


  • Open Access

    Pancreas Transplantation: Indications and Consequences

    by Jennifer L. Larsen

    Pancreas transplantation continues to evolve as a strategy in the management of diabetes mellitus. The first combined pancreas-kidney transplant was reported in 1967, but pancreas transplant now represents a number of procedures, each with different indications, risks, benefits, and outcomes. This review will summarize these procedures, including their risks and outcomes in comparison to kidney transplantation alone, and how or if they affect the consequences of diabetes: hyperglycemia, hypoglycemia, and microvascular and macrovascular complications. In addition, the new risks introduced by immunosuppression will be reviewed, including infections, cancer, osteoporosis, reproductive function, and the impact of immunosuppression medications on blood pressure, lipids, and glucose tolerance. It is imperative that an endocrinologist remain involved in the care of the pancreas transplant recipient, even when glucose is normal, because of the myriad of issues encountered post transplant, including ongoing management of diabetic complications, prevention of bone loss, and screening for failure of the pancreas graft with reinstitution of treatment when indicated. Although long-term patient and graft survival have improved greatly after pancreas transplant, a multidisciplinary team is needed to maximize long-term quality, as well as quantity, of life for the pancreas transplant recipient.


  • Heel ultrasonography is not a good screening tool for bone loss after kidney and pancreas transplantation

    by Lynn R Mack-Shipman, Donna M O'Grady, Judi M Erickson, Craig W Walker, Timothy E Moore, Tab W Burkman, James T Lane, Jennifer L Larsen

    Solid organ transplant recipients, particularly simultaneous pancreas kidney recipients, are at high fracture risk. We tested whether quantitative ultrasonography (QUS) of the heel predicts bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) in solid organ transplant recipients. Thirty-eight transplant recipients (22 Female/16 Male) were studied. Spine and hip BMD was measured with a Hologic DXA scanner. 'Stiffness' of the heel was measured with a Lunar Ultrasound densitometer and compared with BMD by DXA. Contributing factors to bone loss were also assessed. Mean age was 43.1 +/- 1.3 yr. Simultaneous pancreas-kidney, kidney, and pancreas alone transplant recipients were assessed. Mean time post-transplantation was 3.0 +/- 0.6 yr. Mean DXA spine T-score was -1.15 +/- 0.22 (mean +/- SEM) and hip T-score was -1.22 +/- 0.20. There was no difference in mean T-score between women and men at the hip or spine. Mean right heel stiffness T-score was -0.97 +/- 0.25. There was no correlation between QUS and DXA at either the hip or spine in women or men. QUS had a false negative rate for identifying osteopenia or osteoporosis of 17% compared with DXA. The false positive rate for identifying osteopenia was 61%. The QUS is an unacceptable tool for identifying those at risk for bone loss after kidney or pancreas transplantation.


  • Pancreas Transplantation Improves Vascular Disease in Patients With Type 1 Diabetes

    by Jennifer L. Larsen, Christopher W. Colling, Tanaporn Ratanasuwan, Tab W. Burkman, Thomas G. Lynch, Judi M. Erickson, Elizabeth R. Lyden, James T. Lane, Lynn R. Mack-Shipman

    OBJECTIVE—Pancreas transplantation (PTX) normalizes glucose and improves microvascular complications, but its impact on macrovascular disease is still debated.